InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Mowry Anna, Chief Financial Officer. Director active across 1 companies, notably Nautilus Biotechnology, Inc.. In total, 5 reports have been published. Total volume traded: €366k. The latest transaction was filed on 27 June 2022 — Acquisition. Regulator: SEC (Form 4). All data is openly available.
Declarations5 total
€14,2945,500 shares@ €2.59890.0058% mcap3.9% of flow
Common Stock
SEC:0001808805-22-000075:0·
Ideal exit: 24 Mar 2023 (T+270)
€61,03415,000 shares@ €4.068934.7% of flow
Common Stock
SEC:0001808805-21-000023·
Ideal exit: 21 Aug 2022 (T+270)
€61,03415,000 shares@ €4.06890.025% mcap16.7% of flow
Common Stock
SEC:0001808805-21-000023:0·
Ideal exit: 21 Aug 2022 (T+270)
€114,96417,500 shares@ €6.569465.3% of flow
Common Stock
SEC:0001808805-21-000012·
Ideal exit: 9 May 2022 (T+270)
€114,96417,500 shares@ €6.56940.047% mcap31.4% of flow
Common Stock
SEC:0001808805-21-000012:0·
Ideal exit: 9 May 2022 (T+270)
5 of 5 declarations
About Mowry Anna
Anna Mowry is Chief Financial Officer and Treasurer at Nautilus Biotechnology, Inc. She oversees the financial management of the company, including financial planning and reporting. Her role is essential for ensuring the financial health and growth of the company.
